Hubbry Logo
DimethylamphetamineDimethylamphetamineMain
Open search
Dimethylamphetamine
Community hub
Dimethylamphetamine
logo
8 pages, 0 posts
0 subscribers
Be the first to start a discussion here.
Be the first to start a discussion here.
Contribute something
Dimethylamphetamine
Dimethylamphetamine
Dimethylamphetamine
View on Wikipedia
from Wikipedia
Dimethylamphetamine
INN: Dimetamfetamine
Clinical data
Routes of
administration		Oral
ATC code
  • none
Legal status
Legal status
Identifiers
  • N,N-dimethyl-1-phenylpropan-2-amine
CAS Number
PubChem CID
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC11H17N
Molar mass163.264 g·mol−1
3D model (JSmol)
  • CC(N(C)C)CC1=CC=CC=C1
  • InChI=1S/C11H17N/c1-10(12(2)3)9-11-7-5-4-6-8-11/h4-8,10H,9H2,1-3H3 checkY
  • Key:OBDSVYOSYSKVMX-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

Dimethylamphetamine (Metrotonin), also known as dimetamfetamine (INN), dimephenopan and N,N-dimethylamphetamine, is a stimulant drug of the phenethylamine and amphetamine chemical classes. Dimethylamphetamine has weaker stimulant effects than amphetamine or methamphetamine and is considerably less addictive[1] and less neurotoxic compared to methamphetamine.[2][3] However, it still retains some mild stimulant effects and abuse potential,[4] and is illegal in both the United States and Australia.

Dimethylamphetamine has occasionally been found in illicit methamphetamine laboratories, but is usually an impurity rather than the desired product. It may be produced by accident when methamphetamine is synthesised by N-methylation of dextroamphetamine if the reaction temperature is too high or an excess of methylating agent is used.[5][6]

It is said to be a prodrug of amphetamine/methamphetamine.[7]

See also

[edit]

References

[edit]
Revisions and contributorsEdit on WikipediaRead on Wikipedia

Dimethylamphetamine

View on Grokipedia
from Grokipedia

Dimethylamphetamine, also known as N,N-dimethylamphetamine or dimetamfetamine, is a synthetic organic compound with the chemical formula C11H17N, classified as a tertiary amine derivative of amphetamine. It functions as a central nervous system stimulant, exhibiting pharmacological effects similar to but weaker than those of amphetamine or methamphetamine, including increased alertness and euphoria, while demonstrating reduced potential for addiction and neurotoxicity compared to its analogs. In the United States, dimethylamphetamine is designated as a Schedule I controlled substance under the Controlled Substances Act, indicating high abuse potential and no currently accepted medical use. The compound is frequently identified as a byproduct or impurity in the illicit synthesis of methamphetamine from precursors such as methylephedrine, arising during processes like pyrolysis or reductive amination. Despite its stimulant properties, limited research exists on its precise mechanism of action, which likely involves enhanced release of monoamine neurotransmitters such as dopamine and norepinephrine, though with diminished potency relative to primary amine amphetamines.

Chemistry

Chemical Structure and Properties

Dimethylamphetamine, systematically named N,N-dimethyl-1-phenylpropan-2-amine, has the molecular formula C₁₁H₁₇N and a of 163.26 g/mol. It is a tertiary derivative of , characterized by the substitution of the primary amino group with two methyl groups on the nitrogen atom, resulting in the structure where the chain bears an α-methyl group and the N,N-dimethylamino moiety. This structural modification imparts basic chemical properties typical of aliphatic tertiary amines, including a pKa of approximately 8.69 for the conjugate acid. The molecule contains a chiral center at the α-carbon, leading to two s: the (S)-(+)- and (R)-(-)-forms. The is most commonly prepared and used, while enantiopure forms exhibit distinct physical properties, such as the hydrochloride salt of a single enantiomer melting at 185.9°C compared to 162.0°C for the . The typically appears as a colorless to pale yellow oil with a of about 0.90 g/cm³ at elevated temperatures and boils at 88–89°C under reduced pressure (12 ). Dimethylamphetamine hydrochloride forms white crystalline solids that are soluble in water and polar organic solvents like ethanol, owing to its ionic nature as a salt of a weak base. The compound is relatively stable under standard laboratory conditions but can degrade upon prolonged exposure to light or air, potentially forming oxides or other impurities. Its chemical behavior includes reactivity as a base, forming salts with acids, and susceptibility to Hofmann elimination under harsh basic conditions due to the quaternary ammonium potential.

Synthesis and Precursors

N,N-Dimethylamphetamine is primarily synthesized via of (also known as or P2P) with , involving formation of an intermediate followed by reduction using agents such as in protic solvents like at mildly acidic and ambient to elevated temperatures (e.g., 25–60°C). This method yields the tertiary amine directly, with typical purification involving acid-base extraction, distillation under reduced pressure, and crystallization as the salt to achieve analytical purity. In clandestine contexts, N,N-dimethylamphetamine frequently appears as a route-specific impurity rather than a targeted product, particularly in the hydriodic acid/red phosphorus reduction of ephedrine or pseudoephedrine derived from Ephedra plant extracts, where side reactions during the cleavage of the benzylic hydroxyl group produce trace amounts of the dimethylated analog alongside methamphetamine and amphetamine. The presence of N,N-dimethylamphetamine in methamphetamine samples thus serves as a forensic marker for Ephedra-sourced precursors, distinguishing them from synthetic P2P-based routes. An alternative pathway involves N-methylation of using (formalin) under unbuffered aqueous conditions at , which proceeds via Mannich-type intermediates and yields N,N-dimethylamphetamine within hours, often as an unintended over- product in reductive attempts on precursors. Common precursors across these routes include phenyl-2-propanone and for direct synthesis, for sequential , and / for impurity formation in reduction-based processes; yields in optimized laboratory settings range from 70–90% for , though clandestine variants suffer lower efficiency due to impure reagents and suboptimal conditions. Purification in forensic-documented illicit labs typically employs extraction and acidification, mirroring legitimate techniques but with higher impurity profiles traceable to starting materials.

Pharmacology

Pharmacodynamics

Dimethylamphetamine acts as a substrate for the (DAT), (NET), and (SERT), reversing their normal function to promote efflux of these monoamines into the synaptic cleft, thereby mediating its central effects. This mechanism mirrors that of other amphetamines, involving cellular uptake followed by disruption of vesicular storage via interaction with the (VMAT2) and subsequent reversal of plasmalemmal transporter activity, though empirical data specific to dimethylamphetamine remain limited compared to . The N,N-dimethyl substitution impairs its efficacy as both a releaser and uptake inhibitor relative to primary or secondary analogs, resulting in diminished monoamine overflow. In models, dimethylamphetamine elicits dose-dependent locomotor activation and reinforces self-administration behaviors, indicative of mediation, but with markedly reduced potency versus ; effective doses for locomotion and are approximately 7- to 8-fold higher. For instance, striatal depletion following acute administration is only about one-eighth that induced by equimolar , underscoring weaker DAT substrate efficacy. Serotonergic effects are similarly attenuated, with no persistent depletion observed in mouse or rat despite acute release, contrasting methamphetamine's robust and lasting serotonin reductions.

Pharmacokinetics

Dimethylamphetamine is rapidly absorbed following , exhibiting nearly complete . Peak concentrations in biological fluids, such as sweat, occur within hours after doses of 20-25 mg, consistent with the rapid onset typical of analogs. The compound distributes widely throughout the body, with a estimated at 50-100 and a 1:1 partition ratio between plasma and red blood cells; no irreversible binding to plasma proteins has been observed. Metabolism occurs primarily via N-oxidation to dimethylamphetamine N-oxide, the major metabolite identified in both rat and human studies, with minor pathways involving 2D6-mediated N-demethylation to and subsequent further demethylation to . N-dealkylation accounts for approximately 50% of in the dextro and 20% in the levo , while contributes about 10% for both. Elimination is predominantly renal, with 40-65% of the dose excreted unchanged in under acidic conditions ( 5), rising to about 70% total recovery; N-oxides represent 15-25% of urinary metabolites. The plasma half-life averages approximately 4 hours, ranging from 2.5-5 hours for the dextro and 5-7 hours for the levo , shorter than that of due to efficient N-oxidation and dealkylation pathways. Renal clearance, estimated at 150-300 mL/min, is -dependent, with acidic enhancing ; minor elimination also occurs via sweat. CYP2D6 polymorphisms and urinary variations represent key factors influencing kinetics, potentially leading to inter-individual differences in clearance.

Effects and Toxicity

Acute Physiological and Psychological Effects

N,N-Dimethylamphetamine exerts acute effects in animal models, characterized by dose-dependent increases in operant responding under fixed-interval schedules and substitution in discrimination assays, though with 6- to 12-fold lower potency than . These behavioral changes reflect enhanced alertness and psychomotor activation, mediated by monoamine release, but lack the additional stereotyped responding observed with during non-contingent periods. In self-administration paradigms using monkeys, the compound functions as a reinforcer, suggesting subjective effects akin to and motivation, albeit with reduced efficacy relative to . The (+)-enantiomer demonstrates greater potency, maintaining elevated response rates at intravenous doses of 10–56 μg/kg per injection, while the (-)-enantiomer fails to do so even at 100 μg/kg, highlighting in psychological . Human threshold doses are not empirically established due to limited , but from self-administration suggests effective ranges of approximately 10–50 mg, adjusted for the compound's lower potency and pharmacokinetic differences from . Physiological effects parallel those of other tertiary amine stimulants, including sympathomimetic elevations in and via norepinephrine release, coupled with milder and suppression compared to primary amphetamines; this attenuated profile correlates with reduced hyperthermia-linked risks observed in assays at behaviorally equivalent doses. Lethality in rodents occurs at doses only threefold higher than methamphetamine equivalents, underscoring a narrower therapeutic window despite behavioral similarities.

Chronic Effects and Neurotoxicity

In rodent models, N,N-dimethylamphetamine (N,N-DMA) administration induces degeneration of nerve terminals in the , as evidenced by reduced immunoreactivity and decreased uptake sites, though this effect is less pronounced than with . Unlike , which causes both terminal degeneration and neuronal cell body loss in the , N,N-DMA does not produce cell loss in mice following repeated dosing. Further studies in rats demonstrate that N,N-DMA, even at doses producing equivalent behavioral stimulation to methamphetamine (e.g., 100 mg/kg subcutaneously every 6 hours for 5 doses), fails to cause significant depletions in striatal dopamine or serotonin levels, nor does it lead to long-term reductions in monoamine transporters, indicating a dissociation between its locomotor effects and neurotoxic potential. This reduced neurotoxicity is attributed to N,N-DMA's weaker potency in releasing dopamine compared to methamphetamine, resulting in lower intracellular oxidative stress from dopamine auto-oxidation and subsequent mitochondrial damage. Chronic exposure may still promote tolerance to locomotor and stereotypic effects, as observed in repeated dosing regimens in , potentially involving adaptations in signaling pathways similar to those in other amphetamines. However, direct evidence for markers like or elevation specific to N,N-DMA remains limited compared to methamphetamine analogs. Human data on chronic effects are scarce, with no large-scale longitudinal studies available; inferences derive primarily from its occurrence as an impurity in illicit , where it constitutes a minor fraction and does not appear to exacerbate the neurocognitive deficits (e.g., memory impairment, ) associated with methamphetamine purity. Overall, empirical evidence positions N,N-DMA as less neurotoxic than , though risks of adaptations persist absent definitive clinical trials.

Dependence and Abuse Potential

In primate self-administration studies, N,N-dimethylamphetamine maintains responding under fixed-ratio schedules, but at doses indicating substantially lower reinforcing potency than . For instance, doses of 10 to 56 μg/kg/injection of the (+)- in monkeys produced response rates significantly higher than saline but required higher doses to achieve effects comparable to those of or , reflecting reduced avidness of self-administration. Similarly, in monkeys trained to self-administer , N,N-dimethylamphetamine sustained responding above saline levels yet was approximately 10 times less potent than in maintaining these rates. Discriminative stimulus studies further indicate diminished abuse liability relative to amphetamines. Rats trained to discriminate from saline showed that N,N-dimethylamphetamine substituted for the training stimulus but with 12-fold lower potency than , suggesting weaker generalization to the subjective effects associated with reinforcement and craving. This aligns with behavioral assays where elicited increased unscheduled responding during time-out periods (indicative of heightened motivational drive), whereas N,N-dimethylamphetamine did not, pointing to reduced propensity for compulsive seeking behaviors that underpin dependence. These findings from controlled animal models challenge assumptions of equivalent addiction potential to more potent stimulants like , as N,N-dimethylamphetamine demonstrates clear reinforcing properties without the same intensity of maintenance, substitution, or adjunctive responding. Peer-reviewed data emphasize its lower potency across multiple metrics of liability, though studies remain limited due to its illicit status.

History and Research

Discovery and Early Studies

N,N-Dimethylamphetamine, also known as dimethylamphetamine or by the pharmaceutical name Metrotonin, emerged from early 20th-century efforts to synthesize and evaluate derivatives for potential therapeutic applications as stimulants. Specific details regarding its initial synthesis remain sparsely documented, aligning with the broader context of amphetamine analog exploration that intensified in the 1930s and 1940s amid pharmaceutical interest in agents. Initial pharmacological assessments focused on its capacity to produce stimulation, revealing effects that were notably milder in potency and duration compared to amphetamine itself, prompting researchers to deprioritize further development in favor of more efficacious compounds. This relative weakness in stimulant action contributed to its lack of commercial viability for medical use at the time. Prior to the 1960s, dimethylamphetamine attracted minimal sustained investigation, with available records indicating no large-scale clinical trials or extensive preclinical evaluations.

Animal and Human Studies

In 1989, researchers assessed the neurotoxic potential of N,N-dimethylamphetamine (N,N-DMA) by administering multiple doses to mice and rats, measuring subsequent levels of and serotonin in brain regions such as the and whole . Unlike , which causes persistent depletions, N,N-DMA produced only transient reductions in and no long-lasting serotonin deficits, indicating substantially lower neurotoxic risk in these models. A 1990 study examined behavioral effects of N,N-DMA compared to N-methylamphetamine () in rats under schedules of food-maintained responding and in squirrel monkeys responding under second-order schedules for or food. N,N-DMA elicited weaker rate-increasing effects on operant behavior and lower reinforcing potency than across both species, with reduced disruption of ongoing behaviors at equivalent doses. In a related 1991 investigation, the reinforcing effects of N,N-DMA enantiomers were tested via intravenous self-administration in squirrel monkeys, revealing modest substitution for but lower overall efficacy than analogs, further supporting diminished abuse-related behavioral potency. Human data on N,N-DMA remain sparse, primarily limited to pharmacokinetic and metabolic profiling rather than direct behavioral or toxicological assessments. A 1986 study administered oral doses to healthy volunteers and analyzed urinary metabolites, identifying six primary products including and N-methylamphetamine, with N,N-DMA exhibiting slower elimination compared to but no acute adverse events reported at tested doses. Forensic analyses have detected N,N-DMA and metabolites in via liquid chromatography-mass spectrometry, often in contexts of polydrug use or as a methamphetamine analog, but controlled human trials for efficacy or safety are absent. Despite evidence from animal models of reduced neurotoxicity and behavioral potency relative to methamphetamine, N,N-DMA has not advanced to clinical evaluation for medical applications, such as attention-deficit/hyperactivity disorder treatment, due to its structural similarity to controlled stimulants and regulatory constraints. Ongoing research gaps persist, including long-term human exposure effects and direct comparisons under controlled dosing, with most data derived from analog scheduling rather than dedicated therapeutic investigation.

United States

In the , N,N-dimethylamphetamine is explicitly classified as a Schedule I controlled substance under the (CSA), as codified in 21 U.S.C. § 812 and detailed in the DEA's schedules. This placement, effective since the initial scheduling under the Comprehensive Drug Abuse Prevention and Control Act of 1970 and subsequent listings, subjects it to the strictest controls, prohibiting manufacture, distribution, dispensing, or possession except for limited research purposes approved by the DEA. Schedule I status reflects the DEA's determination that the substance exhibits a high potential for abuse, lacks any currently accepted medical use in treatment, and poses a safety risk without accepted medical supervision—criteria applied uniformly to amphetamine derivatives despite varying empirical profiles for individual analogs. Enforcement emphasizes its role as a methamphetamine analog, with the of 1986 (part of the Anti-Drug Abuse Act, Pub. L. 99-570) enabling prosecution of unlisted but structurally similar substances intended for human consumption as if they were Schedule I drugs, particularly when linked to illicit stimulant markets. The DEA has applied this framework in cases involving designer stimulants resembling N,N-dimethylamphetamine, underscoring its treatment as a derivative due to shared phenylpropylamine backbone and potential for similar pharmacological effects. Violations carry severe penalties, including up to 20 years' imprisonment for first offenses involving trafficking, escalating for repeat or large-scale activities under 21 U.S.C. § 841. Forensic detection often identifies N,N-dimethylamphetamine as a process impurity in methamphetamine seizures, arising from synthetic routes like or Leuckart reactions where incomplete reduction or side methylation occurs. Gas chromatography-mass spectrometry analyses of U.S. seizures have confirmed its presence in crystalline methamphetamine samples, sometimes at levels aiding source attribution, though routine testing primarily targets and may not distinguish it without specialized profiling. This impurity linkage informs DEA intelligence on clandestine labs but highlights scheduling rigidity, as N,N-dimethylamphetamine's isolation yields lower potency effects in limited studies compared to , yet triggers identical prohibitions.

International Controls

Dimethylamphetamine is not explicitly listed in any schedule of the of 1971, which controls -type stimulants such as (Schedule II) and (Schedule II) but omits N,N-dimethylamphetamine and certain derivatives. This absence means international obligations do not mandate specific controls, leaving regulation to national discretion, though structural similarity to scheduled amphetamines often prompts domestic prohibitions. The substance is also not designated as a precursor under the 1988 Convention against Illicit Traffic in Narcotic Drugs and Psychotropic Substances. In , dimethylamphetamine is classified as a Schedule 9 prohibited substance under the Poisons Standard, rendering it illegal for any use, including possession, manufacture, or supply, with no exemptions for medical or purposes except under strict regulatory approval. Aligned jurisdictions, such as those adhering closely to frameworks, similarly prohibit it, reflecting precautionary approaches to amphetamine analogues despite limited documented prevalence of abuse relative to more widely used stimulants like , which faces no international scheduling despite comparable physiological effects in high doses. Within the , dimethylamphetamine lacks uniform supranational control and is not specifically mentioned in EU-wide directives on new psychoactive substances, but member states often regulate it through generic provisions banning substituted amphetamines or analogues under national implementations of the 1971 Convention. Variations exist; for instance, some countries apply risk assessments similar to those for phenethylamine derivatives, prioritizing structural alerts over empirical harm data, leading to scheduling inconsistencies across the bloc compared to unregulated stimulants with established consumption patterns.

Role as a Byproduct in Illicit Production

Dimethylamphetamine (DMA) emerges as an impurity during clandestine synthesis, often resulting from over- of amphetamine intermediates or incomplete reactions involving precursors like and . Such formation occurs particularly when excess methylating agents are used or reaction conditions exceed optimal temperatures, leading to unintended N,N-dimethyl substitution. during processing steps, such as heating or smoking trials in labs, further generates DMA from via at temperatures above 315°C. In forensic profiling of seized , DMA serves as a route-specific marker, detectable in crystals from - or pseudoephedrine-based reductions where side reactions produce it alongside primary products. Analysis of confiscated samples from regions like has identified DMA as one of the most frequent by-products, appearing in multiple batches analyzed via gas chromatography-mass spectrometry (GC/MS). Similarly, international impurity studies of street consistently report DMA traces, distinguishing it from purer pharmaceutical-grade analogs. Detection of DMA in environmental samples, such as , provides indirect evidence of nearby illicit production sites, as synthesis impurities can leach from lab effluents. A study across European cities quantified DMA concentrations up to 10 ng/L, correlating with residues and highlighting its dual role as both a production contaminant and artifact from end-user consumption. These findings enable to map lab activity through elevated local levels exceeding typical smoking-derived inputs. The incidental presence of DMA in illicit batches undermines purity testing protocols, as it dilutes active content and introduces variable neuroactive contaminants that forensic labs must differentiate via targeted impurity profiling. This complicates yield estimations in seizures—where DMA levels can reach 1-5% in impure samples—and elevates concerns from inconsistent dosing in street products, though direct data remains limited to methamphetamine's dominant effects.

Society and Culture

Recreational and Illicit Use

N,N-Dimethylamphetamine exhibits limited documented recreational use, with a notable surge in abuse cases reported in starting in 1998, leading to increased submissions of urine specimens for containing the substance and its metabolites. Many instances of detection occur not from intentional standalone but as a pyrolysis byproduct formed during the smoking of , resulting in its presence in users' alongside and . The compound occasionally appears as an impurity or in illicit production, for example, in a 2022 U.S. of seized samples where one purported methamphetamine crystal contained 97% N,N-dimethylamphetamine hydrochloride. Such occurrences arise from specific synthetic routes or cutting agents used in clandestine manufacturing. Standalone non-medical use remains rare, attributed to its comparatively subdued profile requiring higher doses for effects equivalent to . shows few reports of overdose or high-dependence patterns, though its classification reflects acknowledged abuse liability, with wastewater analyses occasionally using it as an indirect marker for smoking . Critics of stringent analog controls argue that such measures overlook data indicating reduced reinforcing and neurotoxic risks relative to , potentially overemphasizing hypothetical escalation despite sparse severe case documentation.

Comparisons to Other Stimulants

Dimethylamphetamine, specifically N,N-dimethylamphetamine, exhibits weaker central effects than or , with studies indicating it is approximately sevenfold less potent in inducing behavioral activation related to modulation. This reduced potency correlates with lower reinforcing efficacy, as evidenced by diminished self-administration in preclinical models compared to , suggesting decreased abuse liability. Unlike , which causes persistent depletion of and serotonin terminals through and , N,N-dimethylamphetamine fails to produce such neurotoxic outcomes even at doses yielding equivalent acute locomotor stimulation, dissociating its behavioral pharmacology from long-term neuronal damage. In contrast to methamphetamine's high addiction potential, driven by robust dopamine efflux and rapid tolerance development, dimethylamphetamine's milder profile—characterized by slower onset and attenuated reward circuit activation—positions it as less prone to compulsive use patterns observed with primary amphetamines. This empirical differentiation underscores opportunities for policy consideration of compounds with separable stimulant and toxic effects, potentially filling therapeutic niches for conditions like attention-deficit/hyperactivity disorder where is prioritized, though risks of diversion into non-medical use necessitate stringent oversight. Relative to legal stimulants such as and alcohol, dimethylamphetamine demonstrates lower acute lethality and dependence escalation in analogous pharmacological assessments, yet endures Schedule I classification without approved medical outlets, exemplifying regulatory asymmetries. Multi-criteria evaluations rank alcohol highest in overall harm due to its volume of use, (e.g., over 3 million global deaths annually attributable to ), and societal costs, surpassing amphetamine-class drugs in integrated risk metrics, while 's cardiovascular and carcinogenic burdens similarly exceed those of low-potency analogs like dimethylamphetamine in margin-of-exposure analyses. These disparities fuel debates on evidence-based scheduling, where zero-tolerance for synthetic stimulants contrasts with tolerated harms from entrenched legal substances, potentially overlooking causal gradients in and dosage-dependent outcomes.

References

  1. https://pubchem.ncbi.nlm.nih.gov/compound/Dimethylamphetamine
  2. https://hmdb.ca/metabolites/HMDB0041880
  3. https://www.sciencedirect.com/topics/pharmacology-toxicology-and-pharmaceutical-science/dimetamfetamine
  4. https://analyticalsciencejournals.onlinelibrary.wiley.com/doi/abs/10.1002/dta.2419
  5. https://www.chemicalbook.com/ChemicalProductProperty_EN_CB51334145.htm
  6. https://www.swgdrug.org/Monographs/Dimethylamphetamine.pdf
  7. https://erowid.org/archive/rhodium/chemistry/shulgin.meta-dma.radioiodination.html
  8. https://pubmed.ncbi.nlm.nih.gov/32608093/
  9. https://downloads.regulations.gov/FDA-2022-P-0509-0007/content.pdf
  10. https://www.cdc.gov/niosh/docs/2003-154/pdfs/9106.pdf
  11. https://www.sciencedirect.com/science/article/abs/pii/S037907381200494X
  12. https://pubmed.ncbi.nlm.nih.gov/15893897/
  13. https://pubmed.ncbi.nlm.nih.gov/2765865/
  14. https://pubmed.ncbi.nlm.nih.gov/2338643/
  15. https://repository.ubn.ru.nl/bitstream/handle/2066/147775/mmubn000001_250015994.pdf
  16. https://pubmed.ncbi.nlm.nih.gov/3673111/
  17. https://pubmed.ncbi.nlm.nih.gov/23640382/
  18. https://doi.org/10.1007/BF02245154
  19. https://pubmed.ncbi.nlm.nih.gov/9383014/
  20. https://www.sciencedirect.com/science/article/pii/S0006899397008019
  21. https://www.researchgate.net/publication/20390109_Evaluation_of_the_neurotoxic_potential_of_NN-dimethylamphetamine_an_illicit_analog_of_methamphetamine
  22. https://link.springer.com/article/10.1007/BF02245154
  23. https://pmc.ncbi.nlm.nih.gov/articles/PMC3666194/
  24. https://www.caymanchem.com/product/11556/n-n-dma-hydrochloride
  25. https://www.sciencedirect.com/science/article/pii/0006899389902473
  26. https://www.sciencedirect.com/science/article/pii/S0022356525129911
  27. https://pubmed.ncbi.nlm.nih.gov/12175795/
  28. https://www.deadiversion.usdoj.gov/schedules/orangebook/c_cs_alpha.pdf
  29. https://www.law.cornell.edu/uscode/text/21/812
  30. https://www.dea.gov/drug-information/drug-scheduling
  31. https://pubs.acs.org/doi/10.1021/ac9005588
  32. https://www.sciencedirect.com/science/article/abs/pii/S0379073806000302
  33. https://pmc.ncbi.nlm.nih.gov/articles/PMC7327898/
  34. https://www.incb.org/documents/Psychotropics/forms/greenlist/2022/Green_List_E.pdf
  35. https://www.odc.gov.au/controlled-substances/list/dimethylamphetamine
  36. https://www.euda.europa.eu/publications/european-drug-report/2024/new-psychoactive-substances_en
  37. https://pubmed.ncbi.nlm.nih.gov/15538957/
  38. https://journals.sbmu.ac.ir/medlab/article/download/21485/16398
  39. https://www.jstage.jst.go.jp/article/jhs/50/4/50_4_389/_pdf
  40. https://www.sciencedirect.com/science/article/abs/pii/S0379073802001901
  41. https://go.gale.com/ps/i.do?id=GALE%257CA143437969&sid=googleScholar&v=2.1&it=r&linkaccess=abs&issn=03790738&p=AONE&sw=w
  42. https://www.sciencedirect.com/science/article/abs/pii/0006899389902473
  43. https://scholarscompass.vcu.edu/cgi/viewcontent.cgi?article=3840&context=etd
  44. https://www.researchgate.net/publication/322798605_Ecstasy_to_addiction_Mechanisms_and_reinforcing_effects_of_three_synthetic_cathinone_analogs_of_MDMA
  45. https://pubmed.ncbi.nlm.nih.gov/12774190/
  46. https://www.nature.com/articles/srep08126
  47. https://pmc.ncbi.nlm.nih.gov/articles/PMC7649209/
Add your contribution
Related Hubs
Contribute something
User Avatar
No comments yet.